Carteolol ophthalmic Pregnancy and Breastfeeding Warnings

Brand names: Ocupress

Medically reviewed by Drugs.com. Last updated on Aug 3, 2023.

Carteolol ophthalmic Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Comments:
-A risk for intra uterine growth retardation has been shown when beta-blockers are administered orally.
-Signs and symptoms of beta blockade (e.g., bradycardia, hypotension, respiratory distress and hypoglycemia) have been reported in neonates when beta-blockers have been administered until delivery.
-Neonates should be monitored during the first days of life.

Animal studies have revealed increased resorptions and decreased fetal weights. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references